
Takeda takes senior head from Sanofi
pharmafile | December 19, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Sanofi, Takeda, andrew plump
Dr Andrew Plump will be joining Takeda in February from Sanofi to lead its global R&D operations as chief medical and scientific officer.
Reporting directly to Christophe Weber who is the firm’s president and chief operating officer, Plump’s appointment follows the planned retirement of Tadataka ‘Tachi’ Yamada who currently sits in the role.
Plump takes more than 25 years’ experience in the pharma industry and academia to the firm. His expertise spans across a number of disease areas with emphasis in cardiovascular, metabolism and neuroscience.
Most recently Plump served at Sanofi as the senior vice president of its Research & Translational Medicine unit, and deputy to the president of R&D based in Paris. Prior to that he worked at Merck as its Worldwide Cardiovascular Research head.
“I am fully confident that Andy, with his deep experience in drug discovery and development and his past work in areas directly relevant to Takeda, will sustain and enhance our best-in-class R&D enterprise,” says Weber.
Related Content

Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …






